Although previous studies have shown that the expression of some NK cell receptors (NKG2D, NKp30, DNAM-1, CD16, and 2B4) may be low in patients with breast cancer (36), the prognostic or diagnostic value of this information remains unclear. This evidence concerns the gene CD226 and breast cancer.